A phase II study of neoadjuvant bevacizumab plus docetaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Feb 2013 Planned end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 06 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.